Press release
Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs
Idiopathic pulmonary fibrosis primarily occurs in older adults and disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-grade fevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy, laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone, and N-acetyl cysteine are used alone or combination for the treatment.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/idiopathic-pulmonary-fibrosis-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By route of administration, Idiopathic Pulmonary pipeline drugs are segmented into
• Inhalation
• Parenteral
• Others
By Trial Phase, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
By Company, Idiopathic Pulmonary Fibrosis pipeline drugs are segmented as:
• Johnson & Johnson Services, Inc. (U.S.)
• Immune Works, Inc. (U.S.)
• Hoffmann-La Roche AG (Switzerland)
• Celgene Corporation (U.S.)
• Biogen, Inc. (U.S.)
• Fibro Gen (U.S.)
• Bristol-Myers Squibb (U.S.)
• Promedior, Inc. (U.S)
Space Analysis:
Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.
• In August 2017, Fibro Gen, Inc. announced positive top line results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
• In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/idiopathic-pulmonary-fibrosis-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Report Description:
Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Idiopathic Pulmonary Fibrosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Idiopathic Pulmonary Fibrosis disease pipeline drugs development. This report studies the dynamics of the Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Idiopathic Pulmonary Fibrosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/idiopathic-pulmonary-fibrosis-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis of each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/idiopathic-pulmonary-fibrosis-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1049073 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for Idiopathic
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
Juvenile Idiopathic Arthritis Therapeutics Market
JIA is also known as juvenile idiopathic arthritis and is the most common inflammatory arthritis of childhood, musculoskeletal pain is a common symptom in childhood and is usually benign and self-resolving. JIA is affected to children who are under age 17. Recognizing rare but treatable causes, including inflammatory, malignant and infectious etiologies, remains a constant challenge. According to the American College of Rheumatology, Juvenile idiopathic arthritis affects one in 1000…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
